Microneedle-enhanced drug delivery: fabrication, characterization, and insights into release and permeation of nanocrystalline imiquimod
Transcutaneous delivery systems bear several advantages over conventional needle-based injections. Considering the low bioavailability and poor water-solubility of imiquimod, a manufacturing process has been developed to incorporate imiquimod as suspended nanocrystals in different formulations. In t...
Saved in:
Published in | Frontiers in Drug Delivery Vol. 4 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
27.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Transcutaneous delivery systems bear several advantages over conventional needle-based injections. Considering the low bioavailability and poor water-solubility of imiquimod, a manufacturing process has been developed to incorporate imiquimod as suspended nanocrystals in different formulations. In this study, three formulations - fast-dissolving microneedle arrays that contain nanocrystalline imiquimod in a poly (vinyl)alcohol matrix and two semisolid preparations-were characterized and compared. The results show that microneedle arrays have an advantage over the semisolid preparations regarding
in vitro
release and permeation characteristics. Microneedle arrays facilitate
ex vivo
permeation, thus reducing the applied dose by 93% compared to the semisolid formulations. Additionally, the amount of imiquimod permeated after 24 h maintained the same level even when the contact time of the formulation with the skin is less than 1 hour. In conclusion, our results highlight the great potential of advanced microneedle based delivery systems and foster the further evaluation of this approach. |
---|---|
Bibliography: | Aharon Azagury, Ariel University, Israel Edited by: Fiorenza Rancan, Charité University Medicine Berlin, Germany Reviewed by: Yang Chen, China Medical University, China |
ISSN: | 2674-0850 2674-0850 |
DOI: | 10.3389/fddev.2024.1425144 |